Last reviewed 2026-06-10 · How we verify

Otitis media due to susceptible Streptococcus pneumoniae — Treatment Landscape & Competitive Intelligence

Otitis media due to susceptible Streptococcus pneumoniae (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Otitis media due to susceptible Streptococcus pneumoniae, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Pfizer Inc. · 1 drug in Otitis media due to susceptible Streptococcus pneumoniae

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Otitis media due to susceptible Streptococcus pneumoniae:

• Otitis media due to susceptible Streptococcus pneumoniae treatment updates — RSS
• Otitis media due to susceptible Streptococcus pneumoniae treatment updates — Atom
• Otitis media due to susceptible Streptococcus pneumoniae treatment updates — JSON

Cite this brief

Drug Landscape (2026). Otitis media due to susceptible Streptococcus pneumoniae — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/otitis-media-due-to-susceptible-streptococcus-pneumoniae. Accessed 2026-06-10.

Related

• Otitis media due to susceptible Streptococcus pneumoniae full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing